DBV Tech grabs $25M C round for allergy drug trials

A pair of new investors--InnoBioFund and Lundbeckfond Ventures--has taken the lead on a $25.5 million Series C round for France's DBV Technologies, And the biotech plans to use that money to fuel its work on new therapies for severe food allergies.

According to Genetic Engineering & Biotechnology News the French company gained FDA clearance on clinical trial work for its peanut allergy therapy with Phase Ib studies now underway. The NIH is supporting Phase II work, which is scheduled to get started at the middle of this year. Shire and Alto Invest joined the round with existing investors Sofinnova Partners and Alk Abello.

- here's the story from Genetic Engineering & Biotechnology News

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.